a year ago

ExpressionEdits Secures $13 Million Seed Funding to Advance Protein Expression Technology

  • ExpressionEdits, a Cambridge, UK-based biotechnology company optimizing protein expression using AI and proprietary intronization technology, raised $13 million in Seed funding led by Octopus Ventures and redalpine, with participation from BlueYard Capital, Wilbe Capital, Acequia Capital, Amino Collective, and Hawktail

  • The company intends to use the funds to accelerate candidate selection for preclinical studies and develop a pipeline of protein-based therapeutics

  • Founded in 2021 by Dr

  • Kärt Tomberg, Professor Allan Bradley, and Dr

  • Liliana Antunes, ExpressionEdits provides proprietary intronization technology for gene design, which mimickes the natural genetic landscape

  • Genetic Syntax Engine is a computational gene editing platform that uses advanced AI and deep biological insights to predict and redesign genes to unlock protein expression across therapeutic modalities.

      • ProblemHealthcare

      "ExpressionEdits is addressing the challenge of optimizing protein expression, which is crucial for developing effective gene therapies and recombinant proteins. Traditional methods often lead to suboptimal protein production and manufacturing issues, hindering the development of innovative therapeutics."

      Solution

      "ExpressionEdits uses proprietary intronization technology and an AI-driven Genetic Syntax Engine to redesign genes and predict protein expression levels. This approach aims to improve the effectiveness and precision of gene therapies, allowing for lower doses to achieve therapeutic levels, minimizing toxicity, and expanding the genetic toolbox to target specific tissues and increase protein expression."

      Covered on